Janus kinase (JAK) inhibition may lead to increased serum ACE levels and a temporary rise in ACE 2 activity in patients with RA, suggesting a redistribution and shedding of renin–angiotensin–aldosterone system (RAAS) components between the synovium and the bloodstream. This evidence concerns the gene ACE and rheumatoid arthritis.